Biomea Fusion Inc
BMEA1.400USD
+0.050+3.70%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
83.31MMarket Cap
LossP/E TTM
More Details of Biomea Fusion Inc Company
Biomea Fusion, Inc. is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.
Biomea Fusion Inc Info
Ticker SymbolBMEA
Company nameBiomea Fusion Inc
IPO dateApr 16, 2021
CEOHitchcock (Michael J.M)
Number of employees106
Security typeOrdinary Share
Fiscal year-endApr 16
Address1599 Industrial Road
CitySAN CARLOS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94070
Phone16509809099
Websitehttps://www.biomeafusion.com/
Ticker SymbolBMEA
IPO dateApr 16, 2021
CEOHitchcock (Michael J.M)
Company Executives of Biomea Fusion Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Rainer M. (Ramses) Erdtmann
Mr. Rainer M. (Ramses) Erdtmann
President, Co-Founder, Principal Financial Officer, Chief Operating Officer, Director
President, Co-Founder, Principal Financial Officer, Chief Operating Officer, Director
2.54M
+0.39%
Dr. Eric Aguiar, M.D.
Dr. Eric Aguiar, M.D.
Lead Independent Director
Lead Independent Director
200.00
--
Dr. Michael J.M. (Mick) Hitchcock, Ph.D.
Dr. Michael J.M. (Mick) Hitchcock, Ph.D.
Interim Chief Executive Officer, Director
Interim Chief Executive Officer, Director
--
--
Dr. Juan Pablo Fras
Dr. Juan Pablo Fras
Chief Medical Officer, Head of Diabetes
Chief Medical Officer, Head of Diabetes
--
--
Dr. Elizabeth Faust, Ph.D.
Dr. Elizabeth Faust, Ph.D.
Independent Director
Independent Director
--
--
Ms. Sumita Ray, J.D.
Ms. Sumita Ray, J.D.
Independent Director
Independent Director
--
--
Ms. Meichiel Jennifer Weiss
Ms. Meichiel Jennifer Weiss
Senior Director, Investor Relations and Corporate Development
Senior Director, Investor Relations and Corporate Development
--
--
Ms. Julianne Averill
Ms. Julianne Averill
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Rainer M. (Ramses) Erdtmann
Mr. Rainer M. (Ramses) Erdtmann
President, Co-Founder, Principal Financial Officer, Chief Operating Officer, Director
President, Co-Founder, Principal Financial Officer, Chief Operating Officer, Director
2.54M
+0.39%
Dr. Eric Aguiar, M.D.
Dr. Eric Aguiar, M.D.
Lead Independent Director
Lead Independent Director
200.00
--
Dr. Michael J.M. (Mick) Hitchcock, Ph.D.
Dr. Michael J.M. (Mick) Hitchcock, Ph.D.
Interim Chief Executive Officer, Director
Interim Chief Executive Officer, Director
--
--
Dr. Juan Pablo Fras
Dr. Juan Pablo Fras
Chief Medical Officer, Head of Diabetes
Chief Medical Officer, Head of Diabetes
--
--
Dr. Elizabeth Faust, Ph.D.
Dr. Elizabeth Faust, Ph.D.
Independent Director
Independent Director
--
--
Ms. Sumita Ray, J.D.
Ms. Sumita Ray, J.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Dec 10
Updated: Wed, Dec 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
10.77%
Janus Henderson Investors
5.30%
Butler (Thomas Andrew)
4.21%
Erdtmann (Rainer M)
3.64%
The Vanguard Group, Inc.
3.07%
Other
73.01%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
10.77%
Janus Henderson Investors
5.30%
Butler (Thomas Andrew)
4.21%
Erdtmann (Rainer M)
3.64%
The Vanguard Group, Inc.
3.07%
Other
73.01%
Shareholder Types
Shareholders
Proportion
Investment Advisor
18.56%
Investment Advisor/Hedge Fund
11.15%
Individual Investor
8.07%
Hedge Fund
5.76%
Research Firm
1.13%
Venture Capital
0.38%
Bank and Trust
0.23%
Other
54.74%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
263
22.54M
49.35%
-2.60M
2025Q3
272
25.14M
60.50%
-3.63M
2025Q2
276
28.77M
47.84%
+7.56M
2025Q1
278
21.21M
74.70%
-6.86M
2024Q4
285
23.08M
78.27%
-290.82K
2024Q3
275
23.37M
79.31%
-174.19K
2024Q2
268
23.56M
100.68%
-7.90M
2024Q1
255
31.41M
92.62%
-1.83M
2023Q4
241
28.07M
97.10%
-2.19M
2023Q3
219
30.27M
94.53%
+527.87K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
7.24M
12.17%
+1.81M
+33.26%
Jun 30, 2025
Butler (Thomas Andrew)
2.97M
5%
--
--
Mar 31, 2025
Erdtmann (Rainer M)
2.49M
4.19%
-40.00K
-1.58%
Jun 30, 2025
The Vanguard Group, Inc.
1.88M
3.16%
+501.63K
+36.40%
Jun 30, 2025
Aisling Capital Management LP
2.05M
3.44%
+1.25M
+156.49%
Jun 30, 2025
Heights Capital Management, Inc.
3.84M
6.45%
+3.84M
--
Jun 30, 2025
Woodline Partners LP
1.74M
2.93%
+1.50M
+624.05%
Jun 30, 2025
Cormorant Asset Management, LP
3.57M
6%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
720.15K
1.21%
-1.24M
-63.32%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Micro-Cap ETF
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
State Street SPDR S&P Biotech ETF
0%
iShares Russell 3000 ETF
0%
View more
ProShares Ultra Nasdaq Biotechnology
Proportion0.01%
iShares Micro-Cap ETF
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
Invesco Nasdaq Biotechnology ETF
Proportion0.01%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
State Street SPDR S&P Biotech ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Biomea Fusion Inc?
The top five shareholders of Biomea Fusion Inc are:
Fidelity Management & Research Company LLC holds 7.24M shares, accounting for 12.17% of the total shares.
Butler (Thomas Andrew) holds 2.97M shares, accounting for 5.00% of the total shares.
Erdtmann (Rainer M) holds 2.49M shares, accounting for 4.19% of the total shares.
The Vanguard Group, Inc. holds 1.88M shares, accounting for 3.16% of the total shares.
Aisling Capital Management LP holds 2.05M shares, accounting for 3.44% of the total shares.
Fidelity Management & Research Company LLC holds 7.24M shares, accounting for 12.17% of the total shares.
Butler (Thomas Andrew) holds 2.97M shares, accounting for 5.00% of the total shares.
Erdtmann (Rainer M) holds 2.49M shares, accounting for 4.19% of the total shares.
The Vanguard Group, Inc. holds 1.88M shares, accounting for 3.16% of the total shares.
Aisling Capital Management LP holds 2.05M shares, accounting for 3.44% of the total shares.
What are the top three shareholder types of Biomea Fusion Inc?
The top three shareholder types of Biomea Fusion Inc are:
Fidelity Management & Research Company LLC
Janus Henderson Investors
Butler (Thomas Andrew)
Fidelity Management & Research Company LLC
Janus Henderson Investors
Butler (Thomas Andrew)
How many institutions hold shares of Biomea Fusion Inc (BMEA)?
As of 2025Q4, 263 institutions hold shares of Biomea Fusion Inc, with a combined market value of approximately 22.54M, accounting for 49.35% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -11.15%.
What is the biggest source of revenue for Biomea Fusion Inc?
In --, the -- business generated the highest revenue for Biomea Fusion Inc, amounting to -- and accounting for --% of total revenue.
